Annual ROE
-145.64%
-98.65%-209.94%
30 September 2022
Summary:
NeuBase Therapeutics annual return on equity is currently -145.64%, with the most recent change of -98.65% (-209.94%) on 30 September 2022. During the last 3 years, it has fallen by -98.65% (-209.94%).NBSE ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
-103.52%
+12.95%+11.12%
30 September 2023
Summary:
NeuBase Therapeutics quarterly return on equity is currently -103.52%, with the most recent change of +12.95% (+11.12%) on 30 September 2023.NBSE Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBSE ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | -209.9% | -69.9% |
| 5 y5 years | +44.1% | +63.3% |
NBSE ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time | -100.5% | -100.7% |
NeuBase Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2023 | - | -103.52%(-11.1%) |
| June 2023 | - | -116.47%(+2.1%) |
| Mar 2023 | - | -114.12%(+3.1%) |
| Dec 2022 | - | -110.72%(+13.7%) |
| Sept 2022 | -145.64%(+209.9%) | -97.34%(+24.0%) |
| June 2022 | - | -78.51%(+17.1%) |
| Mar 2022 | - | -67.07%(+6.9%) |
| Dec 2021 | - | -62.72%(+2.9%) |
| Sept 2021 | -46.99%(-15.4%) | -60.93%(-4.4%) |
| June 2021 | - | -63.74%(+4.3%) |
| Mar 2021 | - | -61.09%(-11.2%) |
| Dec 2020 | - | -68.82%(-23.8%) |
| Sept 2020 | -55.55%(-78.7%) | -90.31%(-64.7%) |
| June 2020 | - | -255.82%(-43.8%) |
| Mar 2020 | - | -455.02%(+30.1%) |
| Dec 2019 | - | -349.82%(+24.0%) |
| Sept 2019 | -260.55%(-100.8%) | -282.09%(+99.7%) |
| June 2019 | - | -141.26%(+43.1%) |
| Mar 2019 | - | -98.73%(+10.9%) |
| Dec 2018 | - | -88.99%(-8.4%) |
| Sept 2018 | 31.59 K%(<-9900.0%) | -97.19%(+55.0%) |
| June 2018 | - | -62.69%(-10.7%) |
| Mar 2018 | - | -70.24%(-25.4%) |
| Dec 2017 | - | -94.19%(-5.8%) |
| Sept 2017 | -104.23%(+1.0%) | -99.96%(-3.4%) |
| June 2017 | - | -103.50%(-12.2%) |
| Mar 2017 | - | -117.84%(+27.8%) |
| Dec 2016 | - | -92.19%(+14.9%) |
| Sept 2016 | -103.22%(+188.6%) | -80.25%(+27.1%) |
| June 2016 | - | -63.14%(+37.3%) |
| Mar 2016 | - | -45.99%(+19.8%) |
| Dec 2015 | - | -38.38%(-0.1%) |
| Sept 2015 | -35.77%(+4.8%) | -38.42%(-4.8%) |
| June 2015 | - | -40.35%(-3.0%) |
| Mar 2015 | - | -41.61%(-27.6%) |
| Dec 2014 | - | -57.48%(-0.5%) |
| Sept 2014 | -34.13%(-68.2%) | -57.78%(-23.2%) |
| June 2014 | - | -75.21%(-48.5%) |
| Mar 2014 | - | -146.01%(+23.7%) |
| Dec 2013 | - | -118.03%(-23.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2013 | -107.38%(+79.1%) | -153.90%(+20.6%) |
| June 2013 | - | -127.61%(-40.4%) |
| Mar 2013 | - | -214.21%(-67.4%) |
| Dec 2012 | - | -657.16%(-274.2%) |
| Sept 2012 | -59.97%(-156.2%) | 377.26%(+186.5%) |
| June 2012 | - | 131.68%(-26.2%) |
| Mar 2012 | - | 178.38%(+26.5%) |
| Dec 2011 | - | 141.04%(-34.4%) |
| Sept 2011 | 106.69%(-182.5%) | 214.98%(-0.5%) |
| June 2011 | - | 216.12%(-873.8%) |
| Mar 2011 | - | -27.93%(+33.1%) |
| Dec 2010 | - | -20.99%(-75.8%) |
| Sept 2010 | -129.25%(-8.4%) | -86.67%(-144.7%) |
| June 2010 | - | 194.03%(-164.0%) |
| Mar 2010 | - | -303.36%(+81.6%) |
| Dec 2009 | - | -167.03%(-39.3%) |
| Sept 2009 | -141.08%(-288.9%) | -275.32%(-54.3%) |
| June 2009 | - | -602.72%(-104.0%) |
| Mar 2009 | - | 14.98 K%(-757.0%) |
| Dec 2008 | - | -2279.79%(-5436.6%) |
| Sept 2008 | 74.70%(-96.9%) | 42.72%(-106.0%) |
| June 2008 | - | -712.50%(-110.1%) |
| Mar 2008 | - | 7026.97%(-1218.9%) |
| Dec 2007 | - | -628.03%(-12.7%) |
| Sept 2007 | 2396.96%(-408.6%) | -718.99%(+14.1%) |
| June 2007 | - | -630.11%(+278.1%) |
| Mar 2007 | - | -166.65%(-1573.5%) |
| Dec 2006 | -776.83%(<-9900.0%) | 11.31%(-5.2%) |
| Sept 2006 | - | 11.93%(-32.6%) |
| June 2006 | - | 17.70%(+167.8%) |
| Mar 2006 | - | 6.61%(-18.9%) |
| Dec 2005 | 6.35%(-48.4%) | 8.15%(+155.5%) |
| Sept 2005 | - | 3.19%(+525.5%) |
| June 2005 | - | 0.51%(-95.5%) |
| Mar 2005 | - | 11.37%(-4.4%) |
| Dec 2004 | 12.30%(+11.5%) | 11.89%(-38.9%) |
| Sept 2004 | - | 19.45%(+27.5%) |
| June 2004 | - | 15.26%(+130.9%) |
| Mar 2004 | - | 6.61% |
| Dec 2003 | 11.03% | - |
FAQ
- What is NeuBase Therapeutics annual return on equity?
- What is the all time high annual ROE for NeuBase Therapeutics?
- What is NeuBase Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for NeuBase Therapeutics?
What is NeuBase Therapeutics annual return on equity?
The current annual ROE of NBSE is -145.64%
What is the all time high annual ROE for NeuBase Therapeutics?
NeuBase Therapeutics all-time high annual return on equity is 31.59 K%
What is NeuBase Therapeutics quarterly return on equity?
The current quarterly ROE of NBSE is -103.52%
What is the all time high quarterly ROE for NeuBase Therapeutics?
NeuBase Therapeutics all-time high quarterly return on equity is 14.98 K%